Cyclosporin A (CsA) can induce graft-versus-host disease (GVHD) following autologous bone marrow transplantation (ABMT) and autologous peripheral blood stem cell transplantation (APBSCT) in adults. We investigated whether GVHD can be induced following ABMT and APBSCT in childhood, and which cells are involved in the pathogenesis of this syndrome. We conducted a prospective study of 20 children and adolescents with hematological malignancies receiving CsA after ABMT and APBSCT. Skin biopsies were obtained on day 21 after transplantation or in the event of a rash. Immunophenotypic analysis of peripheral blood lymphocytes was performed on days 14, 21, 28 and 60 after transplantation. Clinical GVHD of the skin, confirmed by histological criteria, occurred in five patients. Five patients had no clinical GVHD but had acute GVHD alterations on routine skin biopsy. In all 10 patients with a positive skin biopsy for GVHD, CD4
depletion is also associated with an increased incidence of marrow graft failure and an increase in relapse rate. 4 The procedure-related toxicity is lower after autologous bone marrow transplantation (ABMT) than after allogeneic BMT. In contrast, the higher relapse rates after autologous and syngeneic BMT than after allogeneic BMT are at least partly due to the absence of graft-versus-tumor effect associated with GVHD. 5, 6 A syndrome that clinically resembles acute GVHD has been observed spontaneously in 8% of patients receiving autologous or syngeneic BMT. 7 This syndrome appears to involve only the skin, is generally mild, and is self-limiting. Due to the rarity of this phenomenon, it has not been possible to determine its effects on leukemic relapse rates.
In ABMT, further significant dose escalation with the current conditioning protocols is limited due to unacceptable toxicity. Therefore, interest has focused on methods stimulating immunologically mediated antitumor activity. In animal models, GVHD was induced by treatment with cyclosporin A (CsA) in rats or mice undergoing autologous and syngeneic BMT. 8, 9 In rodents, GVHD is associated with the appearance of autoreactive T lymphocytes directed against class II histocompatibility (HLA-DR or Ia) antigens. 10 Since the majority of acute leukemias and lymphomas express class II MHC antigens, 11 these tumors may be targeted by autoreactive T lymphocytes detecting these antigens. CsA-induced syngeneic GVHD has been demonstrated to have an inhibitory effect on growth of Ia-positive myeloma in rats. 12 This suggests that CsA-induced GVHD may have an additional graft-versus-tumor effect, which is normally absent in autologous and syngeneic BMT.
Encouraged by the results from animal experiments, clinical studies were initiated to induce GVHD by treatment with CsA in ABMT patients. CsA-induced GVHD has been reported after ABMT in adults with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease, 13, 14 acute myeloid leukemia (AML), [15] [16] [17] acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia, 14 and breast cancer. 18 Recently, CsA-induced GVHD has been described in adult patients with lymphoma following autologous peripheral blood stem cell transplantation (APBSCT). 19 Since the incidence of allogeneic GVHD is lower in children than in adults, 20, 21 in this prospective trial we investigated whether it is possible to induce GVHD in children after ABMT and APBSCT. In addition, we were interested in an assessment of the T cell subsets playing an important role in the pathogenesis of CsA-induced GVHD.
Materials and methods

Patients
Twenty consecutive children and adolescents (12 male and eight female) referred to our hospital were enrolled in this prospective study (Table 1) . Their median age was 12 years (range 3-21 years). Nine patients suffered from AML, seven from ALL and four from NHL. At the time of transplantation, eight patients were in first and 12 patients in second complete remission. One patient (unique patient number (UPN) 206) received a second transplant after he relapsed following the first transplant (UPN 151). The median duration of the first complete remission was 32 months (range 14-119 months) for those patients receiving transplantation during second complete remission. The median duration of current complete remission at the time of transplantation was 6 months (range 3-13 months) for all 20 patients. Twelve patients received an ABMT, six patients an APBSCT, and two patients a combined transplantation of autologous bone marrow and autologous peripheral blood stem cells. This investigation was approved by the Internal Review Board at this institution, and informed consent was obtained from all patients and their parents, as appropriate.
Treatment
In ABMT, approximately 3 × 10 8 nucleated bone marrow cells/kg were harvested from the posterior iliac crest during remission. An erythrocyte-free bone marrow mononuclear cell fraction was obtained by Ficoll-Hypaque densitygradient centrifugation. In APBSCT, peripheral blood stem , intravenously) followed by G-CSF (10 g/kg/day, intravenously) until completion of pheresis. Peripheral blood stem cells were collected using a Cobe Spectra (Cobe Laboratories, Heimstetten, Germany) after recovery of a white blood cell (WBC) count of greater than 2.0 × 10 9 /l. Bone marrow mononuclear cells and peripheral blood stem cells were cryopreserved, unpurged, with 5% dimethylsulfoxide in the vapor-phase of liquid nitrogen. Conditioning therapies are given in Table 1 . Autologous bone marrow cells and peripheral blood stem cells were thawed and reinfused intravenously. This was designated day 0. All patients received CsA at a total dose of 1.5 mg/kg/day, given intravenously as two 4-h infusions daily. CsA was given for 28 days, beginning on the day of transplantation. The CsA blood level was checked every week. G-CSF was administered at a dosage of 10 g/kg/day intravenously beginning on day 1 after transplantation until the WBC count was greater than 5.0 × 10 9 /l. Patients received transplants in single rooms equipped with high-efficiency particulate air filtration systems. They received prophylactic antifungal mouth care in addition to gut sterilization with paromomycin, colistin and nystatin; broad-spectrum antibiotics were given during aplasia. All blood products were irradiated to 30 Gy before administration to patients.
GVHD assessment
The clinical grade of GVHD was recorded daily. Patients were examined for presence of rashes, jaundice, diarrhea, and other indicators of acute GVHD. Stool volume assess-ments, liver and kidney function tests, and blood counts were performed daily. Six-millimeter punch skin biopsies were obtained on day 21 or in the event of a rash. Half of each biopsy was fixed in normal saline and embedded in paraffin wax for conventional histological examination, and half was snap-frozen in liquid nitrogen. The fixed hematoxylin/eosin-stained sections of skin biopsies were independently examined by a dermatopathologist who was blind as to the clinical situation of the patients. The histological diagnosis of acute cutaneous GVHD was established when at least grade 2 acute GVHD changes were present, including basal vacuolar degeneration, spongiosis, dyskeratosis, and an infiltration of lymphocytes in the upper dermis and lower epidermis. 22, 23 The cryostat sections of skin biopsies were stained with two monoclonal mouse antibodies to human CD4 and CD8 antigens (MT310 and DK25; Dako, Hamburg, Germany), using standard immunohistochemical examination by means of an alkaline phosphatase/anti-alkaline phosphatase technique to detect antibody binding.
Immunophenotypic analysis
Ethylenediaminotetraacetate (EDTA) blood samples were collected on days 14, 21, 28 and 60 after transplantation. Cells were analyzed for reactivity with a series of directly staining monoclonal antibodies by means of dual-color immunofluorescence assays using a whole blood staining and lysing method with the Q-Prep system (Coulter, Krefeld, Germany). Antibodies included CD4 (MT310; Dako) and CD8 (UCHT4; Sigma, Deisenhofen, Germany). Two hundred to 10 000 cells falling within the lymphocyte gate were analyzed in each test using automated flow cytometry (EPICS-Profile II; Coulter). Twenty separate tests with anti-CD4 and anti-CD8 monoclonal antibodies in combination with other antibodies were performed in each sample from each patient, and the arithmetic mean was calculated.
Statistical analysis
Arithmetic means, medians, standard deviations, and standard errors of the mean (s.e.m.) were calculated with the SPSS statistical program (SPSS, Chicago, IL, USA). The Wilcoxon rank-sum test was used to compare the percentages of T cell subsets and the CD4/CD8 ratios between the patient groups with positive and negative skin biopsy.
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Results
Results are summarized in Table 1 . All patients showed prompt engraftment following transplantation, reaching absolute neutrophil counts of Ͼ0.5 × 10 9 /l at a median of 11 days (range 8-28 days). Platelet engraftment (platelets, untransfused Ͼ20 × 10 9 /l) was achieved at a median of 25 days (range 10-73 days) post transplant. All patients developed moderate to severe mucositis and required supportive care. There were no significant toxicities such as veno-occlusive disease or renal failure. All patients received full-course CsA without reduction or discontinuation. The median blood CsA level was 66 ng/ml (range 22-123 ng/ml). No patient had manifestations of gastrointestinal or hepatic GVHD.
Induction of GVHD
Five of 20 patients developed clinical GVHD of the skin at a median of 14 days (range 6-15 days) after transplantation. This consisted of an erythematous maculopapular rash involving the face, ears, upper trunk, palms, and soles of the feet. No patients had total erythroderma or bullous lesions. The cutaneous manifestations of GVHD resolved spontaneously within 5-24 days without any treatment such as corticosteroids. In all five patients with clinical GVHD of the skin, grade 2 GVHD was confirmed histologically by skin biopsy. Five patients had no rashes or other manifestations of GVHD but had grade 2 GVHD alterations in a routine biopsy 21 days after transplantation. In all 10 of these patients with a positive skin biopsy for GVHD alterations, CD4
+ lymphocytes were the predominant cells in the epidermis. The CD4 + cells were found in the stromaepithelium interface as well as in the epithelium, with a concentration in the pilosebaceous unit ( Figure 1 ). In contrast to the large infiltration of CD4
+ lymphocytes, only a small number of CD8 + cells was found scattered throughout the dermoepidermal junction zone (Figure 2 ). Neutrophil recovery was not required for the development of autologous GVHD. At the onset of clinical GVHD of the skin, four out of five patients had absolute neutrophil counts of Ͻ0.5 × 10 9 /l. Furthermore, lymphocyte recovery was not necessary for the development of clinical GVHD of the skin. In four out of five patients with cutaneous manifestations of GVHD, the onset of GVHD was observed before peripheral blood lymphocytes exceeded 0.2 × 10 9 /l. Immunophenotypic analysis of peripheral blood lymphocytes on days 14, 21, 28 and 60 revealed a continuous decrease of the percentage of CD4 + lymphocytes following transplantation. Patients with a positive skin biopsy for + lymphocytes in the epidermis of a patient (UPN 150) with histologically proven grade 2 GVHD and who received CsA for induction of autologous GVHD. Skin biopsy was performed on day 21 after ABMT during clinical GVHD of the skin with maculopapular rash affecting the upper trunk. The CD4 + lymphocytes are found in the stroma-epithelium interface as well as in the epithelium, with a concentration in the pilosebaceous unit. The CD4 + cells are stained with monoclonal antibodies directed against CD4 antigen (MT310; Dako), using alkaline phosphatase/anti-alkaline phosphatase technique (original magnification × 250).
Figure 2 Small number of CD8
+ lymphocytes in the epidermis of a patient (UPN 150) with histologically proven grade 2 GVHD and who received CsA for induction of autologous GVHD. Skin biopsy was performed on day 21 after ABMT during clinical GVHD of the skin with maculopapular rash affecting the upper trunk. There are only a few scattered CD8
+ lymphocytes in the epidermo-dermal junction zone. The CD8 + cells are stained with monoclonal antibodies directed against CD8 antigen (DK25; Dako), using the alkaline phosphatase/anti-alkaline phosphatase technique (original magnification × 250).
GVHD had a significantly higher percentage of CD4 + cells (Wilcoxon rank-sum test, P Ͻ 0.01) than patients with a negative skin biopsy on days 14, 21, 28 and 60 after transplantation (Figure 3a) . In contrast, the percentages of CD8 + lymphocytes increased from day 14 to day 28 following transplantation. Patients with a positive skin biopsy for GVHD had a significantly lower percentage of CD8 + cells (Wilcoxon rank-sum test, P Ͻ 0.01) than patients with a negative skin biopsy on days 14, 28 and 60 (Figure 3b) . The CD4/CD8 ratios decreased in both patient groups from day 14 to day 60 following transplantation. Patients with a positive skin biopsy for GVHD had a significantly higher CD4/CD8 ratio (Wilcoxon rank-sum test, P Ͻ 0.01) than patients with a negative skin biopsy on days 14, 21, 28 and 60 after transplantation (Figure 3c) .
Outcome
At the time of the last follow-up visit, seven of the 10 patients with a positive skin biopsy for GVHD were alive and well without relapse at a median of 1192 days (range 419-1514 days). Three patients (UPN 144, 175 and 151) with a positive skin biopsy subsequently relapsed at 71, 71 and 799 days, respectively, after autotransplant. The two patients with very early relapses 71 days after transplantation (UPN 144 and 175) died of relapse. The patient with late relapse 799 days after ABMT (UPN 151) achieved second complete remission after chemotherapy and received a second APBSCT (UPN 206). CsA was administered following the second transplant at the same dosage as given following the first transplant. This patient again developed GVHD of the skin, confirmed histologically by skin biopsy, and remained in complete remission 596 days after the second transplant. Three of the 10 patients with a negative skin biopsy for GVHD were alive without relapse at 497, 539 and 639 days after transplantation. Seven of the 10 patients with a negative skin biopsy for cutaneous + (a) and CD8 + (b) lymphocytes and CD4/CD8 ratios (c) after transplantation. The percentages of cells expressing CD4 (a) and CD8 (b) and the CD4/CD8 ratio (c) in the patient groups with positive () and negative (˿) skin biopsy for GVHD were compared on different days after transplantation. Each data point represents the arithmetic mean from 20 separate tests. Each bar represents the arithmetic mean Ϯ s.e.m. of 10 patients. *Statistically significant (P Ͻ 0.01) using Wilcoxon rank-sum test.
GVHD (one receiving a transplant during the first complete remission and six receiving transplants during the second complete remission) relapsed at a median of 151 days (range 25-298 days) after autotransplant. Five of the seven patients with relapse died of relapse. One patient with relapse (UPN 172) achieved a third complete remission after chemotherapy and remained in complete remission 487 days following an unrelated donor bone marrow transplant.
Discussion
In this prospective study, we used CsA to induce GVHD in children and adolescents with hematological malignancies following ABMT and APBSCT. This is the first study to be conducted in people of this age; all previous studies have been carried out only in adults. [13] [14] [15] [16] [17] [18] [19] Fischer et al 25 evaluated the effect of age on the induction of syngeneic GVHD after syngeneic bone marrow transplantation and CsA therapy in rats. They found a dramatic decline in the incidence of syngeneic GVHD with increasing age of the animals. From these results, it could be expected that CsA-induced GVHD develops more frequently in children than in adults. Interestingly, we observed clinical GVHD of the skin in five of 20 patients (25%) and positive skin biopsies for histopathologic grade 2 acute GVHD in 10 of 20 patients (50%). This frequency is comparable with the data of studies in adults with a reported frequency of histologically proven GVHD of the skin between 33% 15 and 100%. 13 Our results indicate that GVHD can be safely and reproducibly induced by 1.5 mg/kg/day CsA intravenously for 28 days following ABMT and APBSCT in childhood. In agreement with previous studies, [13] [14] [15] [16] [17] [18] CsA-induced GVHD was mild, self-limiting, and confined to the skin. No patients exhibited extracutaneous manifestations of GVHD. Interestingly, Barredo et al 26 recently reported an unusual case of severe and progressive GVHD following ABMT and CsA therapy. Corresponding to the data in adults, [13] [14] [15] [16] [17] [18] [19] histologically proven CsA-induced GVHD developed after a conditioning regimen that included chemotherapy alone and chemotherapy with total body irradiation and was observed following both ABMT and APBSCT (Table 1) . In all cases, acute GVHD of the skin developed during the initial phase of engraftment while the patients were receiving CsA. This finding corresponds with the data of previous clinical studies with a reported onset of CsA-induced GVHD during CsA treatment in the majority of patients. [13] [14] [15] In contrast, in animal studies, CsA-induced GVHD was not seen while rats were receiving CsA but was observed 12-40 days after cessation of CsA therapy. 8 The difference between clinical and animal studies suggests that species-specific differences exist in the clonal expansion of autoreactive T cells.
Following transplantation, we observed a decrease in the percentage of CD4 + lymphocytes, an increase in the percentage of CD8
+ lymphocytes, and a decrease in the CD4/CD8 ratio ( Figure 3) in agreement with other studies on lymphocyte recovery after ABMT and APBSCT. 27, 28 Interestingly, we found a significantly higher percentage of CD4 + cells, a significantly higher CD4/CD8 ratio, and a significantly lower percentage of CD8 + cells (P Ͻ 0.01) in patients with a positive skin biopsy for GVHD than in patients with a negative skin biopsy (Figure 3 ). Immunohistochemical examination of skin biopsies from all 10 patients with histopathologic grade 2 GVHD revealed a large infiltration of CD4 + cells and only a small number of CD8 + cells (Figures 1 and 2 ). These results of immunophenotypic analysis of peripheral blood lymphocytes and of immunohistochemical staining of skin biopsies suggest that CD4
+ lymphocytes play an important role in the pathogenesis of CsA-induced GVHD. Because these patients were referred to our center during remission, tumor cells were not available to perform cell-mediated lysis assays of lymphocytes after transplantation.
In studies in rats, both CD4 +29, 30 and CD8 +10,12 cells have been implicated in the induction and development of syngeneic GVHD. In syngeneic GVHD of the mouse, T cell clones isolated from spleens expressed CD4 antigen and T cell receptor V␤ chains and proliferated to self MHC class II antigens. 31 Their data are consistent with the involvement of a self-class II-specific CD4 + T cell in murine syngeneic GVHD. In humans, Hess et al 32 described the effector cells associated with autologous GVHD in patients with breast cancer as being CD8
+ T lymphocytes expressing the ␣/␤ T cell receptor. These effector cells recognized MHC class II antigens in association with a peptide from the invariant chain (CLIP). However, Horn et al 33 found that the intradermal T cells were mostly CD4
+ cells in patients with breast cancer who received CsA and interferon-␥ after ABMT. These data are consistent with our findings in skin biopsies of patients with GVHD changes and suggest that CD4 + cells play an important role in the pathogenesis of CsAinduced GVHD.
Although seven of the 10 patients with a skin biopsy positive for GVHD are alive without relapse, this study does not allow one to draw conclusions regarding the antitumor effect of CsA-induced GVHD following autologous transplantation. A larger number of patients with longer follow-up is needed to determine whether CsA-induced GVHD is associated with an improved relapse-free survival. Furthermore, additional approaches may be useful in enhancing antitumor activity. Interferon-␥ increases the expression of MHC class II antigens on tumor cells and their susceptibility to lysis by autoreactive T cells that recognize this cell surface antigen. 12 It has been demonstrated that CsA-induced GVHD can be augmented by interferon-␥. 34 Ratanatharathorn et al 35 reported that interferon-␣ administration can both induce autologous GVHD and enhance autologous GVHD induced by CsA. In addition, interleukin-2 amplifies antitumor activity and shows synergism with CsA in induction of a potent graftversus-tumor effect. 36 In future studies, the combination of CsA, interferon and interleukin-2 may induce maximal antitumor activity following ABMT and APBSCT. 
